Israel
Name: KAMADA
Slogan: Specialty Plasma-Derived Therapeutics
Description: Kamada is a growing commercial-stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions. The company is a leader in the specialty plasma-derived field focused on diseases with limited treatment alternatives, with 6 FDA-approved products selling in over 30 countries. The company is advancing an innovative development pipeline targeting areas of significant unmet medical need.
Founded: 1990
Industries: Biopharma, Biotechnology, Health Care, Health and Wellness
Headquarter: Not available
Last Investment: Not available
Last Investment Investors: Not available
KAMADA is a prominent player in the biopharmaceutical sector, with a strong focus on rare and serious conditions. With 6 FDA-approved products being sold in over 30 countries, the company has showcased robust market presence. KAMADA's dedication to addressing areas of significant unmet medical need through innovative development pipeline serves as a testament to its commitment to driving healthcare advancements. Established in 1990, the company operates within the realms of biopharma, biotechnology, health care, and health and wellness, positioning itself as a multifaceted contributor to the medical industry. The absence of publicly available information regarding the last investment and the associated investors indicates the need for further insights into KAMADA's recent financial activities.
